Despite improvements in corneal transplantation, anti-angiogenic and anti-lymphangiogenic factors remain to be be identified. CD160 is an anti-angiogenic target: its expression seems to be restricted to some immune cells and to activated endothelial cells. We hypothesized that CD160 is expressed in blood and lymphatic human corneal neovessels and is involved in corneal graft rejection pathogenesis
After informed consent, patients enrolled for corneal graft surgery at the Robert Debré University Hospital, Reims, France, will be included. Routine general and eye examination including cornea photographs will be performed. During surgery, a quarter of patients' cornea and of donors' corneoscleral rim will be spared for immunohistochemistry analyzes.
Study Type
OBSERVATIONAL
Enrollment
20
Immunohistochemistry and clinical analyses on patients and corneas
Damien JOLLY
Reims, France
RECRUITINGMicro-vascular densities
neovascularization scores quantification of blood (anti-ERG+/anti-D2-40-) and lymphatic (anti-ERG+/anti-D2-40+) vascular structures ; Percentages of those vascular structures marked with anti-CD160
Time frame: 1 year
Percentages of those vascular structures marked with anti-CD160 and/or CD105 and/or aSMA
Time frame: 1 year
Evaluation of clinical blood vascular densities on photographs with help of ImageJ software
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.